Purple Biotech (PPBT) Accumulated Expenses (2015 - 2025)
Purple Biotech (PPBT) posted quarterly Accumulated Expenses of $797000.0 for Q4 2025, up 15.17% year-over-year from $692000.0 in Q4 2024, and up 15.17% quarter-over-quarter from $692000.0 in Q4 2024.
Purple Biotech (PPBT) Accumulated Expenses (2015 - 2025) Analysis & Trends
Purple Biotech (PPBT) has reported Accumulated Expenses for 10 consecutive years, with $797000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses rose 15.17% year-over-year to $797000.0; the TTM figure through Dec 2025 stood at $797000.0 (up 15.17% YoY), while the FY2025 annual figure was $797000.0, up 15.17% from the prior year.
- Accumulated Expenses advanced to $797000.0 in Q4 2025 per PPBT's latest filing, from $692000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.6 million in Q4 2022 and bottomed at -$859000.0 in Q1 2021.
- Historically, Accumulated Expenses has averaged $633111.1 across 5 years, with a median of $692000.0 in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 135.56% — and 2024, when it sank 72.55%.
- Purple Biotech's Accumulated Expenses stood at $1.5 million in 2021, then jumped by 135.56% to $3.6 million in 2022, then decreased by 29.91% to $2.5 million in 2023, then tumbled by 72.55% to $692000.0 in 2024, then rose by 15.17% to $797000.0 in 2025.
- Business Quant data shows PPBT's Accumulated Expenses at $797000.0 in Q4 2025, $692000.0 in Q4 2024, and $2.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Purple Biotech | 130.35 | 130.35 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 797,000.00 |
| Dec 31, 2024 | 692,000.00 |
| Dec 31, 2023 | 2.52 Mn |
| Dec 31, 2022 | 3.60 Mn |
| Sep 30, 2022 | -859,000.00 |
| Jun 30, 2022 | -859,000.00 |
| Dec 31, 2021 | 1.53 Mn |
| Sep 30, 2021 | -859,000.00 |
| Mar 31, 2021 | -859,000.00 |
| Dec 31, 2020 | 880,000.00 |
| Dec 31, 2019 | 255,000.00 |
| Dec 31, 2018 | 852,000.00 |
| Dec 31, 2016 | 76,000.00 |
| Dec 31, 2015 | 123,000.00 |